Mirum Pharmaceuticals, Inc.
MIRM
$44.31
-$0.08-0.18%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 38.31% | -67.12% | 42.22% | 2.54% | 29.11% |
| Total Depreciation and Amortization | -5.81% | -0.46% | 0.25% | 13.68% | 0.46% |
| Total Amortization of Deferred Charges | 4.09% | -1.89% | 4.18% | -1.69% | 3.76% |
| Total Other Non-Cash Items | 29.23% | 69.41% | -45.84% | 41.18% | -48.80% |
| Change in Net Operating Assets | -571.64% | -150.45% | 519.90% | -103.32% | 421.50% |
| Cash from Operations | 61.31% | -227.21% | 204.76% | -125.00% | 191.54% |
| Capital Expenditure | -105.00% | 88.95% | 76.77% | -5,892.31% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2,534.64% | 103.70% | 75.18% | -- | -- |
| Cash from Investing | -2,617.00% | 103.55% | 75.20% | -559,261.54% | 99.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 19.08% | 38.23% | -47.02% | 505.06% | -41.45% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 19.08% | 38.23% | -47.02% | 505.06% | -32.19% |
| Foreign Exchange rate Adjustments | 176.50% | -1,667.05% | 173.95% | -205.31% | 4.63% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2,192.06% | 95.39% | 85.43% | -519.86% | 198.71% |